GlassScriptPhysician profile
Whitney Nicole Smith
NPI 1366028698
$2,354.72
in general payments reported to CMS, 2019-2025
19 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $155 · 2023: $600 · 2024: $727 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,188 · Education: $12.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.53 |
| Education | $12.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $460.99 | 2024-2025 | Fetroja |
| Abbvie INC. | $404.38 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $209.25 | 2024-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $196.71 | 2022-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Aimmune Therapeutics, INC. | $187.72 | 2023-2025 | Vowst |
| Merck Sharp & Dohme LLC | $185.59 | 2022-2024 | Zerbaxa, Dificid, Recarbrio |
| Astellas Pharma US INC | $143.48 | 2023-2024 | Cresemba |
| Gilead Sciences, INC. | $129.25 | 2022-2024 | Veklury |
| Insmed, INC. | $95.66 | 2023-2025 | Arikayce |
| Dexcom, INC. | $91.50 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $47.47 | 2024-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $45.86 | 2024-2025 | |
| Novo Nordisk INC | $43.00 | 2022-2024 | Rybelsus |
| Cequr Corporation | $23.51 | 2025 | Cequr Simplicity |
| Dynavax Technologies Corporation | $22.57 | 2025 | Heplisav-B |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.05 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2025 | |
| Eagle Pharmaceuticals, INC. | $15.25 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.48 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.